A Platform Proven at Unprecedented Scale
The COVID-19 pandemic accelerated the clinical and regulatory validation of mRNA LNP technology at a pace that would otherwise have taken a decade. Within two years of the initial sequencing of the SARS-CoV-2 spike protein, billions of doses of mRNA vaccine had been manufactured, distributed globally, administered under emergency authorisation, and then fully approved by the FDA and EMA. The safety, immunogenicity, and manufacturing scalability of the mRNA LNP platform were demonstrated at a scale that no preclinical model could have predicted.
The scientific and industrial community that built the COVID-19 vaccine supply chain did not then stand still. The formulation scientists, manufacturing engineers, regulatory professionals, and clinical researchers who learned their trade on vaccine programmes are now applying the same platform to a new generation of therapeutic applications, each of which presents its own formulation challenges and clinical expectations.
Personalised Cancer Vaccines: mRNA as Precision Medicine
The most scientifically compelling near-term application of therapeutic mRNA beyond infectious disease is personalised cancer vaccination. Tumour cells accumulate somatic mutations that produce altered proteins called neoantigens, which are not present in normal tissue and are therefore visible to the immune system as foreign. A personalised cancer vaccine encodes the patient’s own tumour neoantigens in an mRNA construct, delivers it via LNP to antigen-presenting cells, and stimulates a T cell response targeted specifically at the tumour.
The clinical results from early trials of personalised mRNA cancer vaccines, including data from Moderna and Merck’s mRNA-4157/V940 programme in melanoma, have shown meaningful improvements in recurrence-free survival in combination with checkpoint inhibitor therapy. BioNTech’s BNT111 programme for melanoma and several other solid tumour programmes are advancing through Phase II, establishing the clinical evidence base for what could become a standard of care in tumour-specific adjuvant therapy.
Rare Genetic Diseases: Protein Replacement by mRNA
For rare genetic diseases caused by loss-of-function mutations that result in absent or non-functional proteins, mRNA therapeutics offer a route to protein replacement that is fundamentally different from enzyme replacement therapy (ERT) or gene therapy. Rather than administering the protein directly (ERT) or permanently correcting the gene (gene therapy), mRNA therapy temporarily restores protein expression by delivering the instructions for the normal protein to the patient’s own cells.
The transient nature of mRNA expression, typically lasting days to weeks depending on the mRNA design and the tissue target, is both a limitation and a safety feature. The treatment must be repeated at regular intervals, but the absence of permanent genomic modification eliminates the risk of insertional mutagenesis associated with viral gene therapy vectors. For diseases like methylmalonic acidemia, propionic acidemia, and other inborn errors of metabolism affecting the liver, mRNA LNP therapy delivered intravenously to hepatocytes is an active area of clinical investigation.
The Formulation Challenges That Remain Unsolved
| Challenge | Clinical Implication | Active Research Direction |
| Extra-hepatic delivery | Most LNP platforms accumulate in the liver after IV administration; reaching lung, muscle, or tumour tissue requires active targeting or alternative routes | Selective organ targeting (SORT) lipids; receptor-targeted LNPs; inhaled LNP delivery for respiratory targets |
| Repeated dosing immunogenicity | PEG-specific IgM responses can cause accelerated blood clearance after repeat doses; some ionisable lipids generate innate immune responses | PEG-alternatives (PEGylation-free LNPs); optimised immunisation schedules; stealth LNP designs |
| mRNA half-life in vivo | Unmodified mRNA is rapidly degraded; modified nucleosides improve stability but add manufacturing complexity | Circular mRNA; self-amplifying mRNA for lower doses; codon and UTR optimisation for enhanced expression |
| Cold chain dependency | Current approved mRNA products require storage at minus 20 or minus 80 degrees C, limiting access in resource-limited settings | Thermostable formulations; lyophilised mRNA LNP products; room-temperature stable excipient systems |
| Manufacturing cost at personalised scale | Personalised cancer vaccines require individual mRNA synthesis per patient; current GMP cost is high | Automated mRNA synthesis platforms; modular GMP; point-of-care manufacturing concepts |
What the Expanding mRNA Pipeline Demands from CDMOs
The breadth of the mRNA therapeutic pipeline, from infectious disease vaccines to oncology, rare disease, and cardiac applications, creates a formulation and manufacturing demand that is qualitatively different from the vaccine manufacturing experience. Cancer vaccine programmes require patient-specific mRNA synthesis and formulation under GMP conditions. Rare disease programmes require precision dosing, specialised patient populations, and regulatory packages adapted to small-batch GMP. Cardiac and pulmonary programmes may require inhaled or locally administered formulations that are outside the IV delivery paradigm of the COVID-19 vaccines.
CDMOs that can support this breadth of application need more than a microfluidics machine and a vial filler. They need formulation scientists who understand the relationship between LNP composition and delivery to specific tissue targets, analytical teams capable of characterising mRNA integrity and potency in complex formulation environments, and regulatory expertise in the evolving framework for mRNA therapeutics beyond the emergency authorisation pathway.
Ardena’s Role in the mRNA Therapeutic Pipeline
Ardena’s nanomedicine facility at Oss is positioned to support mRNA therapeutic development beyond the vaccine applications that established the platform. The formulation team has expertise in ionisable lipid-based LNP systems, and the analytical team at Oss and Assen provides the mRNA integrity, potency, and physicochemical characterisation capabilities needed for regulatory-grade data packages across vaccine and therapeutic applications.
